After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Regeneron Pharmaceuticals, Inc is $80.03B. A total of 1.53 million shares were traded on the day, compared to an average of 1.09M shares.
In the most recent transaction, Bassler Bonnie L sold 760 shares of REGN for 750.00 per share on Nov 20 ’25. After the transaction, the Director now owns 1,548 company shares. In a previous transaction on Nov 20 ’25, Bassler Bonnie L bought 760 shares at 750.00 per share.
Among the insiders who sold shares, Pitofsky Jason disposed of 431 shares on Nov 07 ’25 at a per-share price of $651.43. This resulted in the VP Controller holding 4,233 shares of REGN after the transaction. In another insider transaction, Jason Pitofsky bought 431 shares at $651.00 per share on Nov 07 ’25.
Dividend
The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends. Regeneron Pharmaceuticals, Inc pays an annual dividend of $3.52, resulting in a dividend yield of 0.46%, and it has a price to earnings (P/E) ratio of 18.23.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, REGN has a high of $800.99 and a low of $476.49.
As of this writing, REGN has an earnings estimate of $10.76 per share for the current quarter. EPS was calculated based on a consensus of 20.0 estimates, with a high estimate of $13.16 per share and a lower estimate of $8.89. The company reported an EPS of $12.07 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. REGN’s latest balance sheet shows that the firm has $5.69B in Cash & Short Term Investments as of fiscal 2021. There were $2.70B in debt and $3.93B in liabilities at the time. Its Book Value Per Share was $294.00, while its Total Shareholder’s Equity was $18.77B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for REGN is Buy with a score of 4.32.
